Literature DB >> 31073914

Generation of single-chain Fv antibody fragments against Mu-2-related death-inducing gene in Escherichia coli.

Dimuthu Dhammika Wickramanayake1,2, Jun-Ha Choi1, Juhyun Shin1, Jae-Wook Oh3.   

Abstract

Mu-2-related death-inducing (MuD) gene is involved in apoptosis in tumor cells. Although we have previously produced mouse monoclonal antibodies (MAbs) that specifically recognize human MuD, the application scope of MuD MAbs was restricted due to their mouse origin. Therefore, we attempted the generation of single-chain variable fragment (scFv) against MuD. The heavy- and light-chain variable region genes from two MuD hybridomas were isolated by PCR and joined by DNA encoding a (Gly4Ser1)3 linker. These scFv fragments were cloned into a phagemid vector and expressed as E-tagged fusion proteins in Escherichia coli HB2151. The reactivity of selected Abs was evaluated using ELISA. Selected MuDscFv Abs specifically recognized human MuD, retaining ~ 50% potency of the parent MAbs. MuDscFv-M3H9 recognized the middle region of MuD, while MuDscFv-C22B3 recognized a broad region. Intracellular expression of MuDscFvs-C22B3 protected cells from TRAIL-induced apoptosis. These MuDscFv Abs may help in the study of intracellular signaling pathway centered on MuD and of drug use target and points.

Entities:  

Keywords:  Antibody engineering; Apoptosis; E. coli expression; Mu-2-related death-inducing gene; Single-chain variable fragment antibody

Mesh:

Substances:

Year:  2019        PMID: 31073914     DOI: 10.1007/s11033-019-04852-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  23 in total

1.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

2.  Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.

Authors:  Cécile Ortholan; Jérôme Durivault; Jean-Michel Hannoun-Levi; Mélanie Guyot; Christine Bourcier; Damien Ambrosetti; Stephen Safe; Gilles Pagès
Journal:  Eur J Cancer       Date:  2010-08-20       Impact factor: 9.162

3.  Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs.

Authors:  G Pavlinkova; D Colcher; B J Booth; A Goel; U A Wittel; S K Batra
Journal:  Int J Cancer       Date:  2001-12-01       Impact factor: 7.396

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.

Authors:  Christos Haritoglou; Daniel Kook; Aljoscha Neubauer; Armin Wolf; Siegfried Priglinger; Rupert Strauss; Arnd Gandorfer; Michael Ulbig; Anselm Kampik
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

6.  Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures.

Authors:  Michael Zemlin; Martin Klinger; Jason Link; Cosima Zemlin; Karl Bauer; Jeffrey A Engler; Harry W Schroeder; Perry M Kirkham
Journal:  J Mol Biol       Date:  2003-12-05       Impact factor: 5.469

7.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

8.  A novel protein, MUDENG, induces cell death in cytotoxic T cells.

Authors:  Mi-Rha Lee; Jin Na Shin; Ae Ran Moon; Sun-Young Park; Gilsun Hong; Mi-Ja Lee; Cheol-Won Yun; Dai-Wu Seol; Sujan Piya; Jeehyeon Bae; Jae-Wook Oh; Tae-Hyoung Kim
Journal:  Biochem Biophys Res Commun       Date:  2008-04-04       Impact factor: 3.575

9.  The fifth adaptor protein complex.

Authors:  Jennifer Hirst; Lael D Barlow; Gabriel Casey Francisco; Daniela A Sahlender; Matthew N J Seaman; Joel B Dacks; Margaret S Robinson
Journal:  PLoS Biol       Date:  2011-10-11       Impact factor: 8.029

10.  Bioinformatics in molecular immunology laboratories demonstrated: Modeling an anti-CMV scFv antibody.

Authors:  Chua Kek Heng; Rofina Yasmin Othman
Journal:  Bioinformation       Date:  2006-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.